Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Q2 Revenues Drop 3.3 Percent, Net Loss Surges on Charges

NEW YORK, Aug. 9 (GenomeWeb News) - Harvard Bioscience, which recently announced that it would divest its capital equipment business, today reported second quarter revenue of $21.7 million, a 3.3 percent drop from revenue of $22.5 million in last year's second quarter.

 

The firm's apparatus and instrumentation unit, which it is retaining, brought in revenue of $16.3 million for the quarter, up 4.2 percent year over year from $15.6 million. Revenue for the capital equipment segment dropped a sharp 20.3 percent to $5.4 million from $6.8 million in last year's second quarter.

 

Harvard Bio posted a net loss of $27.4 million, or $.90 per share, compared with a net profit of $298,000, or $.01 per share, year over year. The loss includes asset abandonment and impairment charges of $17.9 million related to the divestiture of the capital equipment business.

 

The firm also disclosed that it has hired investment banking firm Thomas Weisel Partners to help it find a buyer for the capital equipment segment, which includes the Genomic Solutions business. The company said it would use proceeds from the sale to pay down its $15.2 million debt facility and finance tuck-in acquisitions.

 

As of June 30, Harvard Bio had cash and cash equivalents of $13.2 million.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.